Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder – A Claims Database Analysis. (1st August 2022)

• Record Type: Journal Article
• Authors: Kohn, T; Dumas, K; Kohn, J; Agrawal, P; Clifton, M
• Is Part Of: Journal of sexual medicine. Volume 19(2022)Supplement 3
• Page Start: S36
• Page End: S36
• Publication Date: 2022-08-01
• Subjects: Sexual disorders -- Periodicals; Sex -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.jsxm.2022.05.123
• Languages: English
• ISSNs: 1743-6095

Abstract

ABSTRACT: Introduction: Hypoactive sexual desire disorder (HSDD) is estimated to impact ∼10% of women but is commonly undiagnosed. Systemic testosterone therapy (alone or with estrogen) improves libido in women with HSDD; however, concern for adverse effects may limit broad utilization. Objective: Our objective is to describe trends in systemic testosterone for HSDD using a large US claims database. Methods: The TriNetX Diamond Network database was queried: a US health research network of 190 million patients, encompassing healthcare encounters and prescriptions. We identified female patients with HSDD (ICD-10 F52.0) without age limitation from 2010 to September 2021. Testosterone prescription trends (total prescriptions, number per patient, incidence over time [prescriptions/person-day] assessed in 2010-2012, 2013-2015, 2016-2018, and 2019-2021), route of administration, and coadministration with estrogen were extracted. Significance over time was assessed using Chi Square for trend. Results: 37, 491 women diagnosed with HSDD were identified with mean age 46.5±12.4 years. Only 3.9% of women with HSDD (n=1444) were prescribed systemic testosterone (mean age 50.6±10.0 years). Over the past decade, there was a statistically significant increase in testosterone prescriptions for HSDD, specifically for women age 18-40 years and 41-55 years, as seen in Figure 1 (p<0.05). Most prescriptions were for injectable testosterone (56.8%), while 29.3% were for topical testosterone and 13.9% with route unknown. 556 women received only 1 prescription for systemic testosterone, 327 received 2-3 prescriptions, 262 received 4-9 prescriptions, and 299 received 10+ prescriptions. Systemic estrogen was co-prescribed for 543 women and vaginal estrogen was co-prescribed for 259 women; 642 women received no estrogen prescription. Conclusions: Systemic testosterone therapy for HSDD remains rare but its use has increased over time; duration, route, and co-administration with estrogen remain highly variable. Long-term compliance with systemic testosterone therapy remains relatively low. Disclosure: No